Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy

بواسطة Gennari, A, Bruzzi, P, Orlandini, C, Salvadori, B, Donati, S, Landucci, E, Guarneri, V, Rondini, M, Ricci, S, Conte, P
منشور في 2004

Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with primary tumour prognostic features.

بواسطة Ménard, S., Squicciarini, P., Luini, A., Sacchini, V., Rovini, D., Tagliabue, E., Veronesi, P., Salvadori, B., Veronesi, U., Colnaghi, M. I.
منشور في 1994

Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy.

بواسطة Veronesi, U, Salvadori, B, Luini, A, Banfi, A, Zucali, R, Del Vecchio, M, Saccozzi, R, Beretta, E, Boracchi, P, Farante, G
منشور في 1990

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety

بواسطة Baldini, E, Prochilo, T, Salvadori, B, Bolognesi, A, Aldrighetti, D, Venturini, M, Rosso, R, Carnino, F, Gallo, L, Giannessi, P, Conte, P F, Orlandini, C, Bruzzi, P
منشور في 2004

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer

بواسطة Cappuzzo, F, Mazzoni, F, Gennari, A, Donati, S, Salvadori, B, Orlandini, C, Cetto, G L, Molino, A, Galligioni, E, Mansutti, M, Tumolo, S, Lucentini, A, Valduga, F, Bartolini, S, Crinò, L, Conte, P F
منشور في 2004